Articles related to Endocrinology, Diabetes, Metabolism

Emerging reports suggest some patients experience emotional blunting or reduced reward responsiveness after starting GLP-1 receptor agonists. Current evidence remains mixed, and available data have not established a causal relationship between GLP-1 therapy and diminished antidepressant response.

A mathematical modeling study estimated that somatic DNA mutations alone could limit median human life span to roughly 146 to 194 years. The findings add to ongoing research suggesting that aging reflects multiple interacting biological processes rather than a single mechanism.

Reevaluation of major hormone therapy studies has prompted renewed discussion about menopause treatment in breast cancer survivors. Emerging interpretation of older trial data suggests treatment risks may vary by patient characteristics and hormone formulation rather than applying uniformly across all populations.

Older adults with diabetes and frailty frequently experience overtreatment despite individualized glycemic goals that prioritize safety over intensive control. A narrative review highlights deprescribing strategies, relaxed glycemic targets, and medication adjustments intended to reduce hypoglycemia, falls, and treatment burden.

Adults with type 2 diabetes initiating GLP-1 receptor agonists experienced higher rates of nonscarring alopecia than matched users of SGLT-2 or DPP-4 inhibitors. The association persisted across multiple analyses, though absolute risk remained low.

Online claims linking GLP-1 receptor agonists to increased penis size continue attracting patient attention. Available evidence suggests perceived changes may reflect weight loss and erectile function changes rather than anatomic growth.